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Pharmaceutical inhibition of mTOR in the common
marmoset: effect of rapamycin on regulators of
proteostasis in a non-human primate
Matthew Lelegren1,2, Yuhong Liu2, Corinna Ross2,3,4,5, Suzette Tardif2,3,5
and Adam B. Salmon1,2,6*
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University of Texas Health Science Center at San Antonio, San Antonio, TX, USA
Background: Inhibition of mechanistic target of rapamycin (mTOR) has emerged as a viable means to lengthen
lifespan and healthspan in mice, although it is still unclear whether these benefits will extend to other
mammalian species. We previously reported results from a pilot experiment wherein common marmosets
(Callithrix jacchus) were treated orally with rapamycin to reduce mTOR signaling in vivo in line with previous
reports in mice and humans. Further, long-term treatment did not significantly alter body weight, daily
activity, blood lipid concentrations, or glucose metabolism in this cohort.
Methods: In this study, we report on the molecular consequences of rapamycin treatment in marmosets on
mechanisms that regulate protein homeostasis (proteostasis) in vivo. There is growing appreciation for the role
of proteostasis in longevity and for the role that mTOR plays in regulating this process. Tissue samples of
liver and skeletal muscle from marmosets in our pilot cohort were assessed for expression and activity of
components of the ubiquitin-proteasome system, macroautophagy, and protein chaperones.
Results: Rapamycin treatment was associated with increased expression of PSMB5, a core subunit of the 20S
proteasome, but not PSMB8 which is involved in the formation of the immunoproteasome, in the skeletal
muscle and liver. Surprisingly, proteasome activity measured in these tissues was not affected by rapamycin.
Rapamycin treatment was associated with an increased expression of mitochondria-targeted protein
chaperones in skeletal muscle, but not liver. Finally, autophagy was increased in skeletal muscle and adipose,
but not liver, from rapamycin-treated marmosets.
Conclusions: Overall, these data show tissue-specific upregulation of some, but not all, components of the
proteostasis network in common marmosets treated with a pharmaceutical inhibitor of mTOR.
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D
ue to the rapidly growing population of the aged
and elderly, there is increasing need to discover
means to address age-related diseases and pathol-
ogies. A fundamental goal of aging research is to understand
the underlying mechanisms of aging in part to develop
therapeutic interventions to improve healthy aging. In pursuit
of this goal, mechanistic target of rapamycin (mTOR) has
emerged as a targetable cellular signaling pathway to improve
both healthspan and lifespan. mTOR has a central and
evolutionarily conserved role in the regulation of longevity
among eukaryotes including the common laboratory models
yeast, nematodes, flies and mice (15). Inhibition of mTOR
using the macrolide rapamycin was shown to be the first
pharmaceutical intervention capable of reproducible exten-
sion of lifespan in mice (6,7). Rapamycin extends lifespan of
both male and female mice in multiple different genetic
backgrounds, extends lifespan whether administered chroni-
cally or intermittently, and extends lifespan in mice whether
treatments were begun early or late in life (611). There
is also growing evidence that rapamycin can improve
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markers of healthspan in both normally aging mice and
mouse models of age-related disease (1115). It is im-
portant to then clarify whether rapamycin, or more
generally mTOR inhibition, could be used to prevent or
delay age-related diseases clinically. Rapamycin and its
analogs are currently used as part of chemotherapeutic
treatments for organ transplant, prevention of cardiac
stent closure, neuro-genetic diseases and against some
forms of cancer (16). However, the effects of long-term
mTOR inhibition in healthy human subjects is relatively
unknown, though several recent studies suggest a potential to
improve some aspects of age-related dysfunction (1719).
We have utilized the common marmoset (Callithrix
jacchus) as a pre-clinical translational model to explore
the physiological effects of chronic mTOR inhibition in a
healthy non-human primate population. These new-world
monkeys are of relatively small size and short lifespan
compared to other non-human primates commonly used
in biomedical research (2022). Unlike rodents, marmo-
sets have a diverse range of age-related pathologies that are
similar to other primates including humans (21,22). These
are among the most pertinent reasons as to why marmosets
have been suggested as a valuable model organism that
could be used to bridge translation of anti-aging interven-
tions from mouse studies to humans. We have previously
reported results from a pilot study testing a treatment
protocol utilizing an oral administration of rapamycin
to marmosets that achieves clinically therapeutic blood
concentrations of rapamycin and significant reduction
of mTOR signaling (23). We have also shown that long-
term (14 months) rapamycin treatment in this pilot study
does not significantly alter body weight, daily activity,
blood lipid concentrations, or markers of glucose metabo-
lism in the subject marmosets (24).
Here, we report the molecular effects on the regulation
of proteostasis in vivo that are associated with long-
term rapamycin treatment to marmosets. Longevity and
healthspan has been attributed, at least in part, to the
regulation of protein homeostasis or proteostasis (25,26).
For effective proteostasis, abalance is required between the
production and maintenance of properly folded protein
complexes and their eventual degradation or recycling.
Dysregulation of proteostasis can lead to the accumulation
of non-native intracellular protein aggregates or misfolded
proteins that can contribute to cellular dysfunction and the
process of aging itself (25,27). It is widely accepted that
mTOR plays a key role in protein synthesis and autophagy
(28). There is also growing appreciation for a role for
mTOR in both the regulation of protein folding via
molecular chaperones and the ubiquitin-proteasome
system (29,30). In this study, we delineate whether long-
term rapamycin treatment of marmosets alters the in vivo
regulation of a wide range of molecular markers of
proteostasis, including the ubiquitin-proteasome system,
protein chaperones, and autophagy.
Methods
Animal subjects
The animal subjects and study design have been described
previously (23,24). In brief, male and female common
marmosets (Callithrix jacchus) between the ages of 7.1
and 9.1 years of age were each treated once daily by
oral dosing of 0.40 mg active rapamycin/day delivered
as eudragit-encapsulated rapamycin in a yogurt vehicle
via syringe. This dosage is roughly equivalent to 1 mg
rapamycin/kg body weight. Animals were housed as pairs
at the Southwest National Primate Research Center
(SNPRC), and all housing and husbandry were approved
by SNPRC Institutional Animal Care and Use Committee.
At the end of trial, animals were sacrificed, and tissues were
collected immediately, flash frozen, and stored at 808C
until further analysis. At sacrifice, multiple tissues includ-
ing muscle, liver, kidney, heart, brain, adipose, spleen,
plasma, etc. were frozen, stored, and shared with colla-
borators. Our studies here focus on liver and muscle due
largely as 1) an attempt to recapitulate previous studies on
proteostasis in rapamycin-treated mice (11,31) and 2) the
availability of significant quantities of these tissues in house.
Immunoblot
Total protein was extracted from frozen tissue samples by
homogenization in RIPA buffer with additional protease
and phosphatase inhibitors (Thermo Scientific, Rock-
ford, IL, USA), followed by centrifuged at 14,000 g at
48C for 15 min and with the resultant supernatant
used for all studies. Equal amounts of protein samples
were separated by electrophoresis using SDS-PAGE and
then transferred to a polyvinylidene fluoride membrane
(Millipore, Billerica, MA, USA). Primary antibodies and
their sources used in this study: phosphorylated and total
ribosomal protein S6, Calnexin, Hsp40, Hsp60, Hsp70,
LC3-B, GAPDH (Cell Signaling, Beverly, MA) and
PSMB5, PSMB8, Clp protease (ClpP) (Abcam, Cambridge,
MA). Alkaline phosphatase-conjugated secondary antibo-
dies (Santa Cruz Biotechnology, Santa Cruz, CA) followed
by ECL reagent were used to visualize protein bands which
were using ImageJ. When possible, protein samples from
all subjects involved in study were analyzed on a single
immunoblot for individual protein tested. For LC3B
assessment, data were collected over multiple immuno-
blots; for each immunoblot, both control and rapamycin-
treated samples were analyzed concurrently. For all,
data were normalized to relative Ponceau S staining of
membrane following all antibody visualization.
Proteasome activity
Frozen skeletal muscle samples were prepared with
Dounce homogenizer in a buffer containing 50 mM
Tris-CL (pH 7.4), 1 mM DTT, 5 mM MgCl2 either with
(26S activity) or without (20S activity) 0.25 mM ATP.
Supernatant from these preparations was used for assays.
Matthew Lelegren et al.
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Triplicate samples of tissue homogenates were assayed in
96 well clear bottom black plates at a final protein content
of 2 mg in 100 mL buffer. For each sample, 1 mL SDS (3%)
and 50 mM Suc-LLVY-AMC substrate were added to each
well. To assess non-specific proteasome activity, replicate
samples were run in the presence of the proteasome
inhibitor MG132 at concentration of 10 mM. Fluorescent
signal of samples was acquired with SpectraMax micro-
plate reader maintained at 378C and rate of activity was
calculated over the linear portion of this readout.
Statistical analysis
To compare differences between control and rapamycin-
treated groups, Student’s t-test was utilized with a p50.05
deemed statistically significant. Pearson’s correlation test
was utilized to assess relationship of inhibition of mTOR
between tissues in rapamycin-treated animals. All results
are presented as means9standard error unless stated
otherwise.
Results
We previously reported that chronic treatment of mar-
mosets with eudragit-encapsulated rapamycin inhibited
mTORC1 in peripheral blood mononuclear cells, liver
and adipose (23). In tissues collected from those same
animals, we show here a similar reduction in skeletal
muscle mTORC1 signaling as represented by reduced
phosphorylation of ribosomal protein S6 (Fig. 1a, b).
Using data collected previously from these same animals
(23), we then asked whether individual marmosets treated
with rapamycin showed the same relative reduction of
mTORC1 across multiple tissues. Even in our small sample
set (7 rapamycin-treated marmosets), we found that the
degree of mTORC1 inhibition in skeletal muscle induced
by rapamycin treatment was positively correlated with
that found in adipose tissue (Fig. 1c) and also tended to
be correlated with that in liver (Fig. 1d). The degree of
mTORC1 inhibition was also significantly correlated
between liver and adipose tissue (R0.81, p0.03).
There was no relationship among tissues in degree of
mTORC1 inhibition in control animals (data not shown).
Due to availability of tissue, and basing on previous
studies in mice (11,31), we focused the remainder of our
study on skeletal muscle and liver. There is growing
evidence that mTOR plays a role in the regulation of
Fig. 1. (a) Immunoblot showing phosphorylated and total ribosomal protein S6 from skeletal muscle of control (lanes indicated with
‘C’) and rapamycin-treated (lanes indicated with ‘R’) marmosets. (b) Quantification of relative levels of phosphorylation of ribosomal
protein S6 (S6) in skeletal muscle generated from immunoblot in A. Data are presented as mean values (9 SEM) for indicated groups
(cd). Plot comparing relative levels of phosphorylated/total S6 ratio in muscle with that found in adipose and liver collected from the
same rapamycin-treated marmosets (n7 total rapamycin-treated animals). Circles represent values generated from samples collected
from an individual animal and line is regression line. Values in each panel give Pearson’s correlation coefficient for indicated
relationship and p value. Data from liver and adipose were presented previously in (23,24).
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protein degradation through the ubiquitin-proteasome
system (30,32). Here, we found that expression of PSMB5,
a catalytic component of the constitutively active 20S
proteasome, showed a 31% increase (p0.01) in skeletal
muscle of rapamycin-treated animals (Fig. 2a, c). We
found a similar increase (p0.02) in PSMB5 expression
in the liver of these animals (Fig. 2b). We also addressed
whether rapamycin upregulated the expression of PSMB8,
a component of the immunoproteasome that responds
to cytokines released in an inflammatory response. In
both skeletal muscle and liver, there was no statistically
significant change in expression of PSMB8 with rapamy-
cin treatment. Next, we tested whether this increase in
constitutive expression of the PSMB5 component of the 20S
proteasome was associated with a change in proteasome
activity. Surprisingly, we found no effect of rapamycin
treatment on 20S-mediated cleavage of a fluorescent pep-
tide substrate in skeletal muscle tissue homogenates
(Fig. 2d). Similarly, we found no effect of rapamycin on
26S-mediated peptide cleavage (Fig. 2d).
Chaperone-mediated folding of protein structure is an
important step in preserving protein homeostasis without
Fig. 2. Quantification of relative abundance of proteasome subunits PSMB5 and PSMB8 in skeletal muscle (a) or liver (b) from control
and rapamycin-treated marmosets. Data are presented as values for each protein normalized using Ponceau S staining of immunoblot
as a loading control. (c) Representative immunoblot for skeletal muscle data presented in (a). (d) Rate of 20S or 26S-mediated cleavage
of fluorescent peptide (Suc-LLVY-AMC) with or without proteasome inhibitor MG132 in samples from skeletal muscle of control
(n5) and rapamycin-treated (n7) marmosets. Data are presented as mean values (9 SEM) for indicated groups. Asterisks
represent pB0.05 for Student’s t-test comparing control to rapamycin values.
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degradation of proteins. We assessed the expression of a
broad range of these cellular chaperones in both muscle
and liver. Calnexin, located in the endoplasmic reticulum,
is a calcium-dependent chaperone that aids in correctly
folding proteins destined for the secretory pathway (33).
Hsp70, along with its co-chaperone Hsp40, plays a role
in protein folding, refolding, complex formation, and
sequestration of toxic protein aggregates (34). Hsp60 and
ClpP are mitochondria-localized chaperones responsible
for maintenance of the mitochondrial proteome and
are upregulated as a part of the mitochondrial unfolded
protein response (35,36). We found no effect of rapamy-
cin on the relative expression of calnexin, Hsp70, of
Hsp40 in either muscle or liver (Fig. 3a, c). However,
both of the mitochondrial-targeted protein chaperones,
Hsp60 (23%) and ClpP (30%), were significantly
increased in muscle from rapamycin-treated marmosets
(Fig. 3a). In contrast, these chaperones were unaffected
by rapamycin in the liver (Fig. 3b).
Autophagy, an intracellular process by which cellular
macromolecules and organelles are recycled, is one of the
key functional outputs of mTOR signaling. Previous studies
show upregulation of autophagy in rapamycin-treated
yeast, flies, and rodents (11,37,38). LC3B is an ubiquitin-
like protein that conjugates to phosphatidylethanolamine
phospholipids during the formation of the autophagosome
forming the autophagosome membrane-bound isoform
LC3B-II. We found no significant alteration in total
LC3B-II levels in either the muscle or liver (Fig. 4).
An increase in the ratio of LC3B-II to the precursor
LC3B-I can be used as one of the hallmarks of the process
of autophagy (39). We found rapamycin treatment asso-
ciated with a significant increase in LC3B-II/LC3BI ratio
in muscle, but not liver, from rapamycin-treated animals
indicative of increased autophagy in this tissue (Fig. 4).
Because of the strong relationship between autophagy and
mTOR signaling, we addressed the effect of rapamycin on
autophagy in an additional tissue collected from marmo-
sets. As predicted, we found that rapamycin is associated
with elevated levels of autophagy (both LC3B-II content
and LC3B-II/LC3B-I ratio) in adipose tissue from these
animals (Fig. 4).
Discussion
Our results show that long-term pharmaceutical inhibi-
tion of mTOR signaling in the common marmoset
Fig. 3. Quantification of relative levels of indicated molecular chaperones in skeletal muscle (a) or liver (b) from control (n5) and
rapamycin-treated (n7) marmosets. Data are presented as mean values (9 SEM) for indicated groups. Data are presented as values
for each protein normalized using Ponceau S staining of immunoblot as a loading control. Asterisks represent pB0.05 for Student’s
t-test comparing control to rapamycin values. (c) Representative immunoblot for skeletal muscle data presented in (a).
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induces mild, though measurable, activation of some of the
molecular components responsible for the regulation of
proteostasis in vivo. In general, these data hint at potential
tissue-specific regulation of these processes. For example,
while we show here evidence for upregulation of autophagy
consistent with mTOR inhibition in skeletal muscle and
adipose tissue, we found no evidence of any change in
autophagy in liver. Similarly, we found rapamycin asso-
ciated with increased expression of mitochondrial chaper-
ones in muscle but not liver. One possible explanation for
this tissue-specificity could be differences among tissues in
the degree of mTOR inhibition in response to rapamycin.
In this and our previous studies, rapamycin reduced S6
phosphorylation to a greater degree in adipose (65%) and
muscle (52%) than that measured in liver (34%) of the
marmoset. In mice treated with rapamycin orally,
a similar disparity of mTOR inhibition among tissues
has also been noted (40). At least part of this could
be explained by tissue differences in bioavailability and
metabolism of rapamycin in the liver (41). It may be
important to address whether these tissue differences
might be minimized by alternative doses of rapamycin or
by use of different mTOR inhibitors.
In tissues from rapamycin-treated marmosets, we ob-
served a general increase in constitutive 20S proteasome
expression, but no change in the expression of a compo-
nent of the immunoproteasome. However, we found no effect
on either 20S or 26S proteasome activity. These findings
are in contrast to a previous study suggesting chronic
treatment of mice with rapamycin increased both proteasome
activity and expression of the immunoproteasome (31).
On the other hand, others have shown a reduction in
immunoproteasome expression and no significant change
in 20S proteasome expression in response to rapamycin
treatment (42). There are considerable differences among
all these studies in terms of species, age of subjects, means
of drug administration, etc. that could be partial causes
of the equivocal findings in regard to rapamycin and
the regulation of proteasome function. However, it will be
important to clearly delineate whether the regulation of
proteasome expression and activity is a critical component
of the pro-longevity effect of mTOR inhibition.
It was curious that we found no effect of rapamycin on
proteasome activity despite evidence for increased levels
of the 20S proteasome subunit PSMB5. One possible
explanation could be that the specific activity of indivi-
dual 20S units is reduced by rapamycin treatment; that is,
there are more 20S subunits assembled, but the individual
activity of each is reduced. Osmulski and Gaczynska
showed that rapamycin is a potent inhibitor of protea-
some activity in vitro (43). Alternatively, this discrepancy
could result due to the relatively non-stressful cellular
Fig. 4. (a) Quantification of LC3B-II levels (left) and LC3B-II/LC3B-I ratio (right) in skeletal muscle, liver, or adipose tissue from
control and rapamycin-treated marmosets. Data are presented as mean values (9 SEM) for indicated groups and normalized to
control-treated samples in each case for clarity of presentation. Asterisks represent pB0.05 for Student’s t-test comparing control to
rapamycin values. (b) Representative immunoblots for data presented in (a).
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environment that might be expected in the case of healthy
marmosets maintained in the lab. It should be noted
that the 20S and 26S immunoproteasome are induced
under stressful conditions (44). The increased capacity to
respond to stress could explain, at least in part, a potential
mechanism linking increased longevity and healthspan
associated with the regulation of proteostasis (45,46).
Molecular chaperones play a broad role in proteostasis
through their functions of protein folding, refolding,
and targeting for degradation. Interestingly, we found
rapamycin increased only those chaperones thought to be
localized to the mitochondria. Hsp60 has been shown to
have pro-survival effects in organisms exposed to oxida-
tive stress and protects against cardiac ischemia and
reperfusion injury (4749). However, RNAi-mediated
downregulation of Hsp60 and ClpP is associated with
reduced C. elegans longevity (50). More generally, the
regulation of the mitochondrial proteome is key to
maintaining proper mitochondrial function. As mito-
chondrial dysfunction is associated with numerous age-
related pathologies (and likely the aging process itself), it
raises an interesting possibility that rapamycin may pro-
long longevity by mediating mitochondrial proteostasis.
mTOR has a known role in mitochondrial biogenesis,
but future studies will be needed to clarify exactly how
this pathway preserves mitochondrial proteostasis.
Our data suggest that, at least for some tissues, there is a
general upregulation of multiple effectors of proteostasis
in marmosets treated with rapamycin. The processes that
make up the proteostasis network are known to have some
degree of cooperativity in the cell. For example, autophagy
and proteasomes have been shown to work together in
degrading cytoplasmic proteins marked by ubiquitination
(51). In mouse brain, rapamycin was shown to upregulate
autophagy that, in turn, induces protein chaperone ex-
pression including that of Hsp60 (52). In our study, it may
be possible that the induction of autophagy, for instance,
is responsible for the increased expression of mitochon-
drial chaperones. This would provide evidence for in-
creased mitochondrial protection through upregulation of
autophagy. Induction of autophagy has been attributed
as the main effector of the benefits resulting from mTOR
inhibition in several animal models of disease. However,
further investigation will be required to address what
role chaperone or proteasome regulation may play in these
benefits.
In this and our previous studies (23,24), we show that
rapamycin-treated marmosets demonstrate clinically re-
levant blood concentrations of rapamycin, significant
reduction of mTOR across multiple tissues, little evidence
for metabolic dysfunction or altered lipid homeostasis,
and evidence for increased cellular proteostasis in vivo.
These studies strengthen the case for using the common
marmoset as a pre-clinical translation model in which to
test interventions thought to delay aging. In the case of
rapamycin, concerns regarding the side-effects of this drug
likely limit its widespread use among a healthy population.
Even with recent studies suggesting positive immune
benefits in geriatric patients free of disease (17), long-term
effects of this drug on longevity are ostensibly impossible
to test in humans. As a relatively short-lived species, the
common marmoset represents a useful model in which we
can test the hypothesis that mTOR inhibition will extend
longevity and improve healthy aging in primates.
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